Interview with the Co-Founder and CEO: ObsEva SA (NASDAQ:OBSV)
Ernest Loumaye, M.D., Ph.D., is Co-Founder and Chief Executive Officer of ObsEva SA. Dr. Ernest Loumaye has brought extensive experience in pharma product development and the management of biopharmaceutical companies to ObsEva. After a brief academic career at Louvain University Hospital, he joined Serono as head of clinical development for reproductive Health — Geneva and Boston. He contributed actively to the worldwide registration of three important biotechnology products. In 2003, Dr. Loumaye joined Ipsen in Paris as Vice President, Medical Sciences. In 2006, Dr. Loumaye co-founded PregLem, a Swiss-based specialty biopharmaceutical company. As CEO, he led the company to the successful European registration of Esmya, its lead product. Gedeon Richter Plc acquired the company in 2010. In 2012, Dr. Loumaye co-founded ObsEva and since then has served as the CEO of the company. Ernest Loumaye was a visiting professor of reproductive endocrinology at Louvain University, Brussels, from 2002 to 2010, where he held a full-time clinical and academic position until 1991. Dr. Loumaye holds M.D., Ph.D. degrees, with a specialization in obstetrics and gynecology from Louvain University, Belgium. He was a research fellow at the National Institute of Child Health and Human Development in the U.S. and is the author of over 90 publications in peer-reviewed journals. Profile
Word count: 2,950
TWST: What is ObsEva today?
Dr. Loumaye: ObsEva is a biopharma company focused on the development of innovative medicines for women's health.